Cencora Plunges 16.7% — A GLP-1 Speed Bump or a Deeper Margin Crisis?
Cencora's stock fell 16.7% after missing earnings and revenue targets, impacted by a slowdown in GLP-1 volumes and the rise of cheaper biosimilars. The episode examines the company's raised guidance and share buyback amidst these challenges.